Bioelectronics Corp (BIEL)

[Hawk05]

Device sales have begun to return following COVID-19 surgery postponements and delays from labor shortages, and J&J said it expects sales to remain stable through the remainder of the year. (Pixabay)
After reshaping itself as a two-sector company with the spinout of its consumer health division this year, Johnson & Johnson posted ongoing gains across its medtech segments—and said it has a “pretty voracious” appetite for device M&A going forward, while it expects rebounds in surgery volume to continue funneling cash into the coffers for the rest of the year.

https://www.fiercebiotech.com/medtech/jj-professes-voracious-appetite-medtech-ma-following-abiomed-megadeal-success